Logo
Revitrane Bundle Offer

Revitrane Bundle Offer

Revitrane

Medical aesthetics
  • CE Marked hyaluronic acid dermal filler range (including HA10 Classic, HA10 Premium, HA10 Volume, Premium Q and Premium Sub Q).
  • Manufactured under ISO 13485 Compliant quality management system.
  • GMP Compliant production facilities as stated by BR PHARM Co., Ltd.
  • Use of medical Grade, high Purity hyaluronic acid raw materials.
  • Product literature references additional certifications such as CE 2292 and EDQM Related quality standards for certain markets.
  • Distributed in the UK through suppliers and pharmacies operating under MHRA Regulated supply chains (e.g., MHRA Licensed brokers or GDP Compliant wholesalers), although individual device listings should be checked directly in official MHRA databases.
Hyaluronic acid dermal filler bundle

Description

The Revitrane Bundle Offer is a multi-product pack of CE-marked Revitrane HA10 hyaluronic acid dermal fillers, designed to give aesthetic practitioners a complete portfolio for fine lines, wrinkle correction, facial contouring, deep volume restoration and non-surgical rhinoplasty. Each filler in the bundle uses high-purity, cross-linked hyaluronic acid and advanced manufacturing technology to ensure smooth tissue integration, low extrusion force, excellent longevity and natural-looking results. The bundle typically contains one syringe of each of the core Revitrane fillers—Classic, Premium, Volume, Premium Q and Premium Sub-Q—allowing tailored treatment of superficial, mid-dermal, deep dermal and subcutaneous indications with high precision and minimal post-treatment swelling.

Bnefits

  • Comprehensive filler portfolio in a single bundle, covering fine lines, moderate and deep wrinkles, volume loss and facial sculpting.
  • All products are based on high-purity cross-linked hyaluronic acid (20 mg/mL) for natural volume and predictable outcomes.
  • Advanced cross-linking and purification processes provide low extrusion force and smooth, controlled injections.
  • Monophasic and biphasic gel options across the range for optimised viscoelastic properties and moldability in different tissue planes.
  • Excellent tissue integration for soft, natural contours and reduced risk of visible lumps or irregularities when correctly injected.
  • Minimal post-treatment swelling and downtime compared with many traditional fillers in the same category, when used appropriately.
  • CE-marked medical devices manufactured under ISO 13485 and GMP quality systems for safety and consistency.
  • Different viscosities and particle sizes (Classic, Volume, Premium, Premium Q, Premium Sub-Q) allow highly tailored, indication-specific treatment planning.
  • Suitable for use in a wide range of facial areas including lips, perioral lines, crow’s feet, nasolabial folds, marionette lines, cheeks, chin, jawline, temples and nose (depending on product).
  • Convenient bundle pricing for clinics, often at a discount compared with purchasing individual syringes separately.

Indications

  • Revitrane Classic: correction of fine lines and light-to-moderate wrinkles in the superficial to mid dermis, including perioral lines, lip contour, crow’s feet, shallow periorbital lines and early forehead lines; subtle lip enhancement and definition.
  • Revitrane Premium: treatment of moderate facial wrinkles and folds such as nasolabial folds and marionette lines, as well as general facial contouring in the mid to deep dermis where a higher viscosity gel is beneficial.
  • Revitrane Volume: restoration of lost volume and structural support in areas such as cheeks, chin and temples; treatment of deeper facial wrinkles and folds where a thicker, more robust filler is required.
  • Revitrane Premium Q: high-cohesivity filler specifically developed for non-surgical rhinoplasty, including smoothing dorsal humps, improving dorsal lines, lifting a drooping nasal tip and correcting minor nasal asymmetries.
  • Revitrane Premium Sub-Q: high-viscosity, strong elastic particle filler for subcutaneous and supraperiosteal injections in deep facial sculpting, including cheek augmentation, chin and jawline contouring and other areas requiring maximum projection and volume.
  • General indication for the entire bundle: temporary correction of age-related volume loss, contour defects and wrinkles in adult patients via intradermal and subcutaneous injection of cross-linked hyaluronic acid fillers by trained medical professionals.

Composition

  • All fillers in the bundle: cross-linked hyaluronic acid 20 mg/mL (HA10 concentration) as the primary active component.
  • Revitrane HA10 Classic: monophasic cross-linked hyaluronic acid gel 20 mg/mL; supplied as 1 x 1 mL pre-filled syringe (needle size typically 30G) for fine lines, perioral and periorbital areas.
  • Revitrane HA10 Premium: monophasic cross-linked hyaluronic acid gel 20 mg/mL; 1 x 1 mL pre-filled syringe (commonly with 27G needles) for transverse forehead lines, cheek area, nasolabial folds and facial contouring.
  • Revitrane HA10 Volume: cross-linked hyaluronic acid 20 mg/mL in a higher viscosity gel; 1 x 1 mL pre-filled syringe (usually with 27G needles) indicated for deep wrinkles, folds and volume restoration; some distributors specify inclusion of 0.3% lidocaine in certain Volume presentations—clinicians should check the specific pack label.
  • Revitrane Premium Q: biphasic cross-linked hyaluronic acid gel 20 mg/mL with high cohesivity and particle size around 600 microns, designed primarily for nasal contouring; typically supplied as 1 x 1 mL syringe with 25G needles; most UK-distributed packs are described as not containing lidocaine.
  • Revitrane Premium Sub-Q: biphasic cross-linked hyaluronic acid gel 20 mg/mL with larger particle size around 800 microns for strong lifting and structural support in cheek and chin augmentation; supplied as 1 x 1 mL syringe with 25G needles.
  • Some product literature for the range additionally references the use of BDDE (1,4-Butanediol diglycidyl ether) as the cross-linking agent at a minimised level, and a purified buffer system; the exact excipient list may vary slightly by product and market, so the individual carton and insert should always be checked for full composition.

Formulation

  • Class III CE-marked injectable medical device line based on cross-linked hyaluronic acid (20 mg/mL).
  • Monophasic gels (Classic, Premium, Volume) designed for smooth extrusion, uniform gel structure and natural tissue integration.
  • Biphasic high-cohesivity gels (Premium Q, Premium Sub-Q) with defined particle sizes for structural support, contouring and reduced migration when correctly placed.
  • Viscoelastic, moldable gel with optimised rheology for specific injection depths: superficial to mid-dermis (Classic), mid to deep dermis (Premium and Volume), and subcutaneous or supraperiosteal planes (Premium Q and Premium Sub-Q).
  • Manufactured using advanced cross-linking and purification technology (including reduced BDDE residue and endotoxin levels) for safety and injectability.

Packaging

  • Bundle composition as typically sold: 5 x 1 mL pre-filled, single-use sterile syringes—one each of Revitrane HA10 Classic, Revitrane HA10 Premium, Revitrane HA10 Volume, Revitrane Premium Q and Revitrane Premium Sub-Q (exact contents may vary slightly by distributor; practitioners should confirm the current bundle configuration on the supplier’s product page).
  • Each individual Revitrane dermal filler box: 1 x 1 mL glass syringe of cross-linked hyaluronic acid gel with ergonomic grip, supplied in a sterile blister pack, plus two sterile hypodermic needles appropriate to the product (typically 30G for Classic, 27G for Volume and Premium, 25G for Premium Q and Premium Sub-Q).
  • Outer carton labelled with product name, batch number, expiry date, CE marking, manufacturer (BR PHARM Co., Ltd.) and key technical information.
  • Intended for professional use only; not packaged or marketed for direct-to-consumer self-injection.

Usage

  • For use only by suitably trained and qualified healthcare professionals experienced in injectable dermal filler techniques and familiar with the Revitrane product range.
  • Before treatment, perform a full medical history, facial assessment and risk/benefit discussion with the patient; obtain informed consent and follow local regulatory requirements.
  • Inspect the packaging and syringe before use; do not use if the blister, syringe or sterility seal is damaged, or if the product is past its expiry date.
  • Cleanse and disinfect the treatment area using appropriate skin antisepsis, taking care to avoid ocular or mucosal contact with the disinfectant.
  • Select the specific Revitrane product according to the indication: Classic for fine lines and delicate areas, Premium for moderate folds and contouring, Volume for deeper wrinkles and volume restoration, Premium Q for non-surgical rhinoplasty, and Premium Sub-Q for deep structural contouring (cheeks, chin, jawline).
  • Inject slowly into the recommended tissue plane for each product (superficial/mid dermis, deep dermis or subcutaneous/supraperiosteal) using appropriate techniques (linear threading, fanning, small aliquots, etc.), taking care to avoid intravascular injection; aspiration and the use of cannulas may be considered according to clinical judgement and training.
  • Do not overcorrect; remember that the gel’s viscoelasticity and tissue hydration will influence the final result after initial settling.
  • After injection, gently mold and smooth the treated area as needed to achieve the desired contour, avoiding excessive pressure.
  • Advise patients to avoid makeup on the treated area for several hours, to avoid extreme temperatures, vigorous exercise, sunbeds, saunas and alcohol for 24–48 hours, and to follow standard post-filler aftercare instructions provided by the clinic.
  • Instruct patients to report immediately any signs of vascular compromise (intense pain, blanching, livedo), visual disturbance, severe swelling or other atypical symptoms, and to seek urgent medical review.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid or any of the excipients listed in the individual product leaflet.
  • History of severe anaphylactic reactions or multiple severe allergies.
  • Injection into or near sites of active skin disease, infection, inflammation or compromised tissue (e.g., acne, herpes simplex, dermatitis) at the proposed treatment area.
  • Presence of permanent or semi-permanent fillers in or near the intended treatment site, unless the practitioner is confident in the safety of combining products.
  • Known bleeding disorders, current use of significant anticoagulant or antiplatelet therapy (relative contraindication; requires individual risk assessment).
  • Pregnancy and breastfeeding (use is generally not recommended due to lack of safety data).
  • Autoimmune disease or immunosuppression where dermal filler treatment is considered high risk (requires specialist assessment).
  • Intravascular injection must be strictly avoided; do not inject into blood vessels or areas with known high-risk vascular anatomy without appropriate training and precautions.

Adverse Effects

  • Common, usually transient effects at or near the injection site: redness (erythema), swelling, tenderness, pain, bruising, itching, firmness or small palpable nodules, all of which typically resolve within days to a couple of weeks.
  • Less common but recognised events: local infections, prolonged edema, delayed-onset nodules or granulomatous reactions, surface irregularities or asymmetry requiring correction.
  • Vascular occlusion due to inadvertent intravascular injection or external compression, which may present with severe pain, blanching, colour change, livedo reticularis, tissue ischemia or necrosis; this is a medical emergency requiring prompt recognition and management.
  • Rare but serious complications associated with dermal fillers in general, particularly in high-risk areas such as the nose and periocular region: vision changes, blindness, stroke or neurological deficits due to embolisation of filler material.
  • Hypersensitivity or allergic-type reactions, which may be immediate or delayed; very rarely, anaphylaxis.
  • Any persistent, unusual or severe adverse effect should prompt urgent clinical review and, where appropriate, reporting to relevant regulatory bodies.

Storage Conditions

  • Store the syringes in their original packaging at controlled room temperature, typically between 1°C and 30°C as specified by the manufacturer; do not freeze.
  • Protect from direct sunlight, excessive heat and moisture.
  • Do not use if the product has been improperly stored, frozen, exposed to extreme temperatures or if the packaging is damaged.
  • Keep out of the reach of children and unauthorised persons.
  • Single-use only: discard any unused product after the treatment session in accordance with local clinical waste regulations.

Duration

The volumising and wrinkle-correcting effects of Revitrane HA10 dermal fillers are generally reported to last around 6\u201312 months, depending on the product used (Classic, Premium, Volume, Premium Q, Premium Sub-Q), injection technique, treatment area, patient metabolism and lifestyle factors. Some deeper, structural treatments with higher-viscosity products (e.g., Volume and Premium Sub-Q) may persist towards the upper end of this range under optimal conditions.

Onset

Immediate volumising and contouring effect on injection, with final results typically evident once initial swelling and any minor bruising have resolved over several days. Hydration and soft-tissue integration effects may continue to refine the appearance over several weeks.

Browse more Medical aesthetics

Top Treatments

Top Cities in the UK